Seeking Alpha

Shares of Hi-Tech Pharmacal (HITK -18.1%) fall off sharply after rival Wockhardt says it landed...

Shares of Hi-Tech Pharmacal (HITK -18.1%) fall off sharply after rival Wockhardt says it landed FDA approval for a generic copy of GlaxoSmithKline's Flonase nasal spray in a development that could dampen sales of the firm's own generic offering.
Comments (1)
  • bu1956
    , contributor
    Comments (41) | Send Message
     
    Lucky they have more products.
    I wonder who is buying all the share that are being sold --which are well over a weeks worth.
    Hope the president is at the San Fran conference--maybe he can find a small company to buy or maybe a company that might find value in HITK or maybe buy back some of the outstanding shares with some of that horde of cash that is on the balance sheet.
    Lots of maybes-- but smart people make lemonade out of lemons
    10 Jan 2012, 03:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs